Madhavbaug Q4 Results: FY22 earnings out - Check PAT, EBIDTA and more

Announcing its Q4FY22 Results, Madhavbaug, a brand of Vaidya Sane Ayurved Laboratories Ltd, reported a 785 per cent growth in net profit after tax (PAT) in FY2021-22. Madhavbaug’s net profit stood at Rs 3.46 crore in FY 22 as compared to Rs 39 lakhs in FY21, as per details given by company.

Madhavbaug, which operates 272 clinics and 2 hospitals spread across eight states in India, saw its gross revenue increase to Rs 75.04 crore in FY22, a 43 per cent rise from Rs 52.37 crore in FY 21 while its EBIDTA grew 66 per cent from Rs 4.36 crore to Rs 7.25 crore during the same period, as per a company statement. 

Commenting on the Q4FY22 Results, Dr Rohit Sane, MD & CEO, Vaidya Sane Ayurved Laboratories Ltd (Madhavbaug), said, “I am happy to announce that Madhavbaug has shown remarkable business performance in FY21-22 achieving pre-covid turnover with strong contribution from all over segments after overturning barriers like lockdowns in initial months of the year. Both our clinics, which include company owned as well as Franchise owned clinics along with hospitals, have recorded highest ever revenues and EBIDTA. During this reporting period, we continued to focus on collaboration with industry market player across our businesses with view to efficient patient services and to drive future growth."

“In FY 2022-23, with a vision to serve patients more efficiently, Madhavbaug is determined to provide patient finance, education model for fellow doctors, empanelment with insurance companies, corporates, NABH approvals for the hospitals and clinics”, he added.